JP2011502131A5 - - Google Patents

Download PDF

Info

Publication number
JP2011502131A5
JP2011502131A5 JP2010531331A JP2010531331A JP2011502131A5 JP 2011502131 A5 JP2011502131 A5 JP 2011502131A5 JP 2010531331 A JP2010531331 A JP 2010531331A JP 2010531331 A JP2010531331 A JP 2010531331A JP 2011502131 A5 JP2011502131 A5 JP 2011502131A5
Authority
JP
Japan
Prior art keywords
trioxolane
dispiro
administered
scheduled
malaria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010531331A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011502131A (ja
JP5559057B2 (ja
Filing date
Publication date
Priority claimed from US11/930,606 external-priority patent/US8067620B2/en
Application filed filed Critical
Publication of JP2011502131A publication Critical patent/JP2011502131A/ja
Publication of JP2011502131A5 publication Critical patent/JP2011502131A5/ja
Application granted granted Critical
Publication of JP5559057B2 publication Critical patent/JP5559057B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010531331A 2007-10-31 2008-10-29 ジスピロ1,2,4−トリオキソラン抗マラリア剤 Active JP5559057B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/930,606 2007-10-31
US11/930,606 US8067620B2 (en) 2005-05-04 2007-10-31 Dispiro 1,2,4-trioxolane antimalarials
PCT/US2008/081579 WO2009058859A2 (en) 2007-10-31 2008-10-29 Dispiro 1,2,4-trioxolane antimalarials

Publications (3)

Publication Number Publication Date
JP2011502131A JP2011502131A (ja) 2011-01-20
JP2011502131A5 true JP2011502131A5 (enExample) 2011-12-15
JP5559057B2 JP5559057B2 (ja) 2014-07-23

Family

ID=40228026

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010531331A Active JP5559057B2 (ja) 2007-10-31 2008-10-29 ジスピロ1,2,4−トリオキソラン抗マラリア剤

Country Status (19)

Country Link
US (1) US8067620B2 (enExample)
EP (1) EP2203457B1 (enExample)
JP (1) JP5559057B2 (enExample)
KR (1) KR101588468B1 (enExample)
CN (1) CN101842377B (enExample)
AU (1) AU2008318819C1 (enExample)
BR (1) BRPI0818121B8 (enExample)
CA (1) CA2702256C (enExample)
CY (1) CY1115148T1 (enExample)
DK (1) DK2203457T3 (enExample)
ES (1) ES2466319T3 (enExample)
HR (1) HRP20140435T1 (enExample)
MX (1) MX2010004601A (enExample)
PL (1) PL2203457T3 (enExample)
PT (1) PT2203457E (enExample)
RU (1) RU2493159C2 (enExample)
SI (1) SI2203457T1 (enExample)
UA (1) UA99742C2 (enExample)
WO (1) WO2009058859A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067620B2 (en) * 2005-05-04 2011-11-29 Medicines For Malaria Venture Mmv Dispiro 1,2,4-trioxolane antimalarials
CN103429607B (zh) 2011-01-31 2016-02-17 百时美施贵宝公司 具有hiv成熟抑制活性的c-17和c-3经修饰的三萜系化合物
CA2874295A1 (en) * 2012-06-13 2013-12-19 Medizinische Universitat Wien Amidophenoxypropanolamines
US10287312B2 (en) 2014-02-14 2019-05-14 The Regents Of The University Of California Cyclic peroxides as prodrugs for selective delivery of agents
EP3526214A1 (en) 2016-10-13 2019-08-21 MMV Medicines for Malaria Venture New anti-malarial agent
EP3309156A1 (en) 2016-10-13 2018-04-18 MMV Medicines for Malaria Venture New anti-malarial agents
US11246854B2 (en) 2017-05-16 2022-02-15 The Johns Hopkins University Ozonides for treating or preventing virus infections
US11072594B2 (en) 2017-06-27 2021-07-27 The Regents Of The University Of California Trioxolane agents
CN110878069A (zh) * 2019-12-09 2020-03-13 南京杰运医药科技有限公司 一种4-吗琳基-2-乙基哌嗪的制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3621062A (en) * 1966-10-25 1971-11-16 Sterling Drug Inc 2-(8-cyclohexyloctanoyl or 7-cyclohexylheptanoyl)-1-naphthol
US3673222A (en) * 1969-11-26 1972-06-27 Sydney Archer 2-(8-cyclohexyloctyl or 7-cyclohexylheptyl)-1,4-naphthoquinone and process for preparation and use thereof
US3682991A (en) * 1970-10-19 1972-08-08 Sterling Drug Inc 3,3,5-trimethylcyclohexyl-alkyl-carboxylic acids
US4978678A (en) * 1986-11-20 1990-12-18 Hoechst-Roussel Pharmaceuticals Inc. 12-halogenated forskolin derivatives
US4916204A (en) 1987-07-31 1990-04-10 Massachusetts Institute Of Technology Pure polyanhydride from dicarboxylic acid and coupling agent
US4816478A (en) * 1987-08-24 1989-03-28 Thornfeldt Carl R Treatment of acquired immunodeficiency syndrome
US5053342A (en) * 1987-12-24 1991-10-01 Litmus Concepts, Inc. Fecal occult blood test reagents
US5559145A (en) * 1988-06-01 1996-09-24 Oxaco S.A. 1,2,4-trioxane derivatives
US5270344A (en) * 1988-06-24 1993-12-14 Stephen Herman Method of treating a systemic disorder using trioxolane and diperoxide compounds
JP2867529B2 (ja) * 1990-01-22 1999-03-08 三菱電機株式会社 投写型表示装置
US5216175A (en) * 1990-03-23 1993-06-01 Sri International Antimalarial analogs of artemisinin
US5219880A (en) * 1991-03-29 1993-06-15 Dermatologic Research Corporation Treatment of viral tumors and hemorrhoids with artemisinin and derivatives
US5510356A (en) * 1991-10-03 1996-04-23 University Of Nebraska Board Of Regents Bisquinolines and processes for their production and use to treat malaria
US5171676A (en) * 1991-10-31 1992-12-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of introducing hydroxyl groups into artemisinin and its derivatives
US5430148A (en) * 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
ATE152630T1 (de) * 1992-07-28 1997-05-15 Procter & Gamble Pharmazeutische zusammensetzung zur topischen anwendung die ein vernetztes kationisches polymer und einen alkoxylierte äther enthält
US5721209A (en) * 1995-02-03 1998-02-24 The Regents Of The University Of California Iron chelator and inhibitor of iron-mediated oxidant injury
US5780675A (en) * 1995-04-28 1998-07-14 The University Of New Mexico Deoxygossylic compounds
US5578637A (en) * 1995-05-03 1996-11-26 University Of Washington Methods of inhibition or killing cancer cells using an endoperoxide
US5817692A (en) * 1995-11-22 1998-10-06 The Johns Hopkins University Endoperoxides useful as antiparasitic agents
US5672624A (en) * 1995-11-22 1997-09-30 The Johns Hopkins University Endoperoxides useful as antiparasitic agents
US5932591A (en) * 1996-12-02 1999-08-03 Johns Hopkins University C3 substituted trioxanes useful as antiparasitic drugs
US6486199B1 (en) * 2001-06-21 2002-11-26 Medicines For Malaria Venture Mmv International Centre Cointrin Spiro and dispiro 1,2,4-trioxolane antimalarials
US6906205B2 (en) * 2002-06-21 2005-06-14 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
US6825230B2 (en) * 2002-06-21 2004-11-30 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trixolane antimalarials
US7371778B2 (en) * 2002-06-21 2008-05-13 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
US20080125441A1 (en) * 2002-06-21 2008-05-29 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
US8067620B2 (en) 2005-05-04 2011-11-29 Medicines For Malaria Venture Mmv Dispiro 1,2,4-trioxolane antimalarials
WO2006123314A2 (en) * 2005-05-18 2006-11-23 Ranbaxy Laboratories Limited Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials

Similar Documents

Publication Publication Date Title
JP2011502131A5 (enExample)
JP7189983B2 (ja) 異常炎症反応に関連する状態を処置するための方法および組成物
JP7469879B2 (ja) 経口送達と生物学的に同等である薬物動態を有する経皮送達システム
RU2314810C2 (ru) Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5,8,14-триазатетрацикло[10.3.1.0 (2,11).0(4,9)] гексадека-2( 11),3,5,7,9-пентаена
EP2292219B9 (en) Transdermal therapeutic system for the administration of rivastigmine
EP3642214A2 (en) Nicotinamide riboside derivatives and their uses
JP2022553934A (ja) 薬学的製剤
JP2017528494A (ja) sGC刺激剤
JP2017518334A5 (enExample)
JP2009504763A5 (enExample)
KR20150093819A (ko) 약제 조성물
JP2006503850A5 (enExample)
JP2022087276A (ja) メマンチン経皮送達システム
US20200179415A1 (en) Highly active drug combination for treatment of hepatitis c virus
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
RU2010121919A (ru) Диспиро 1, 2, 4-триоксоланы как противомалярийные средства
JP2013537915A5 (enExample)
RU2431502C2 (ru) Фармацевтические композиции для лечения сухости глаз
JP2009513713A5 (enExample)
WO2023187599A1 (en) Methods and bioavailable highly permeable compounds for the treatment of viral diseases
JP7232932B2 (ja) Ws-635及び医学におけるその使用
EA030227B1 (ru) Мини-гранулы для пролонгированного высвобождения триметазидина, способ их получения и применение
JP7474760B2 (ja) Task-1およびtask-3チャンネル阻害剤を含有する医薬投薬形態の製造方法、ならびに呼吸障害治療におけるその使用
BG65472B1 (bg) Използване на саредутант и неговите фармацевтичноприемливи соли за приготвяне на лекарствено средство за използване за лечение или профилактика на голямо депресивно разтройство
JP2012509356A (ja) 2−オキソ−1−ピロリジン誘導体を含む持続放出製剤